Fig. 4
Proliferative tumor response to 37.5 mg daily sunitinib over time measured with FLT-PET. Graphs illustrating the percent change in FLT SUVmax from pre-treatment baseline to after 1 (a), 2 (b), 3 (c), or 4 (d) weeks of sunitinib therapy in individual patients. There was an immediate proliferative response to continuous lower-dose sunitinib that was maintained throughout the duration of this study. Green bars represent proliferative response (≥25 % decrease in FLTSUVmax), red bars represent proliferative progression (≥25 % increase in FLT SUVmax), and blue bars represent stable disease (<25 % change in SUVmax). The bars are labeled with the corresponding patient study identification number